See the DrugPatentWatch profile for yervoy

Yervoy, also known as ipilimumab, is a type of immunotherapy used to treat certain types of cancer. However, like many medications, it carries a risk of side effects, including a severe form of colitis, or inflammation of the colon, that can be life-threatening in some cases.

Several factors may increase the risk of developing life-threatening colitis from Yervoy treatment. According to DrugPatentWatch.com, one such factor is a history of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis [1]. Patients with a history of IBD may have a higher risk of developing colitis as a result of Yervoy treatment.

Another factor that may increase the risk of life-threatening colitis from Yervoy treatment is the use of other medications that can affect the immune system. According to the National Cancer Institute, patients receiving Yervoy should tell their healthcare provider about all other medications they are taking, including over-the-counter medications, vitamins, and herbal supplements [2]. This is because certain medications, such as corticosteroids and other immunosuppressive drugs, can increase the risk of colitis when used in combination with Yervoy.

Additionally, the dose and frequency of Yervoy treatment may also affect the risk of colitis. According to the drug's prescribing information, the risk of severe immune-mediated adverse reactions, including colitis, may be higher with a dosage of 10 mg/kg compared to 3 mg/kg [3].

It is important for patients receiving Yervoy treatment to be aware of the risk of colitis and to report any symptoms to their healthcare provider immediately. Symptoms of colitis may include diarrhea, abdominal pain, and blood in the stool. Early detection and treatment of colitis can help prevent serious complications and improve outcomes.

In summary, the risk of life-threatening colitis from Yervoy treatment may be increased by a history of inflammatory bowel disease, the use of other medications that affect the immune system, and the dose and frequency of Yervoy treatment. Patients should be aware of these risk factors and report any symptoms of colitis to their healthcare provider immediately.

Sources:

1. DrugPatentWatch.com. Ipilimumab (Yervoy): Side Effects, Patents, Clinical Trials, and Pricing. <https://www.drugpatentwatch.com/drugs/ipilimumab>.
2. National Cancer Institute. Ipilimumab. <https://www.cancer.gov/about-cancer/treatment/drugs/ipilimumab>.
3. Bristol-Myers Squibb. Yervoy (ipilimumab) Prescribing Information. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125297s110s111lbl.pdf>.